← All trials
NCT06020755
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2023
- Primary completion
- Aug 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Sep 1, 2023
- Last posted
- Sep 5, 2023
- Enrollment
- 17
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Shanghai Junshi Bioscience Co.,Ltd.Collaborator
- Shengjing HospitalCollaborator
- Fudan UniversityCollaborator
- Xiamen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Henan Medical UniversityCollaborator
- University of Electronic Science and Technology of ChinaCollaborator
- Chinese Academy of Medical SciencesReponsible party - principal investigator
- Gansu Provincial Maternity and Child-Care HospitalCollaborator
- Dalian Maternity and Child Care HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.